As filed with the Securities and Exchange Commission on February 3, 2020

Registration No. 333-235951            

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

AMENDMENT NO. 2

TO

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

aTyr Pharma, Inc.

(Exact name of Registrant as specified in its charter)

 

 

Delaware

 

2836

 

20-3435077

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

3545 John Hopkins Court, Suite 250

San Diego, CA 92121

(858) 731-8389

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

Sanjay S. Shukla, M.D., M.S.

President and Chief Executive Officer

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite 250

San Diego, CA 92121

(858) 731-8389

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Sean M. Clayton

Alexa M. Ekman

Cooley LLP

4401 Eastgate Mall

San Diego, CA 92121

(858) 550-6000

Ivan Blumenthal, Esq.

Cliff M. Silverman, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Chrysler Center, 666 3rd Avenue

New York, NY

(212) 935-1300

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box:  

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  

  

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.


 

EXPLANATORY NOTE

This Amendment No. 2 (Amendment No. 2) to the Registration Statement on Form S-1 (Registration Statement) is being filed solely for the purpose of filing Exhibits 1.1 and 10.21 as indicated in Part II of this Amendment No. 2. This Amendment No. 2 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has been omitted.

 

 

 


 

PART II—INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 13.Other Expenses of Issuance and Distribution

The expenses payable by aTyr Pharma, Inc. (the Registrant or the Company) in connection with the issuance and distribution of the securities being registered (other than underwriting discounts and commissions, all of which will be paid by us) are set forth below. Each item listed is estimated, except for the Securities and Exchange Commission (the SEC) registration fee and the Financial Industry Regulatory Authority, Inc. (FINRA) filing fee.

 

 

 

 

 

 

SEC registration fee

$

2,240

    

  

FINRA filing fee

  

3,087

 

 

Legal fees and expenses

  

200,000

 

 

Accounting fees and expenses

  

120,000

 

 

Printing fees and expenses

  

25,000

 

 

Miscellaneous

  

149,673

 

 

Total

$

500,000

 

  

 

 

 

Item 14.Indemnification of Directors and Officers

Section 145 of the Delaware General Corporation Law (DGCL), authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

We have adopted provisions in our restated certificate of incorporation and amended and restated bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

 

any breach of the director’s duty of loyalty to us or our stockholders;

 

any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

 

any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or

 

any transaction from which the director derived an improper personal benefit.   

These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, our amended and restated bylaws provide that:

 

we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

 

we will advance reasonable expenses, including attorneys’ fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.

II-1


 

We have entered into indemnification agreements with each of our directors and certain of our executive officers. These agreements provide that we will indemnify each of our directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the Company or in furtherance of our rights. Additionally, certain of our directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates, which indemnification relates to and might apply to the same proceedings arising out of such director’s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that the Company’s obligations to those same directors are primary and any obligation of the affiliates of those directors to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary. We also maintain a general liability insurance policy which covers certain liabilities of directors and officers of our Company arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended (Securities Act).

The underwriters are obligated under certain circumstances, under the underwriting agreement to be filed as Exhibit 1.1 to this Registration Statement to indemnify us and our officers and directors against liabilities under the Securities Act.

Item 15.Recent Sales of Unregistered Securities

Since January 1, 2017, the Registrant made sales of the unregistered securities discussed below. The offers, sales and issuances of the securities described below were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act and/or, in the case of conversions, Section 3(a)(9) of the Securities Act.

In November 2016, the Registrant entered into a loan and security agreement, as amended (Loan Agreement) with its lenders to borrow up to $20.0 million issuable in three separate tranches.  Pursuant to the terms of the Loan Agreement, the Registrant issued warrants to purchase the Registrant’s common stock to its lenders on three occasions in connection with drawing down each of the tranches.  In total, the Registrant issued warrants to purchase 12,694 shares of its common stock.

In August 2017, the Registrant completed a private placement of common stock and Class X Convertible Preferred Stock, including warrants to purchase common stock, with a select group of institutional investors (the PIPE Offering).  The Registrant issued a total of 419,438 shares of common stock, 2,285,952 shares of Class X Convertible Preferred Stock and warrants to purchase 463,735 shares of common stock which expired on December 31, 2019.

 

 

 

II-2


 

EXHIBIT INDEX

 

 

Incorporated by Reference

 

Exhibit

Number

Exhibit Title

Form

File No.

Exhibit

Filing Date

1.1

Form of Underwriting Agreement

 

 

 

Filed herewith

3.1

Restated Certificate of Incorporation of the Registrant

S-1/A

333-203272

3.2

May 1, 2015

3.2

Certificate of Amendment to Restated Certificate of Incorporation of the Registrant

8-K

001-37378

3.1

June 28, 2019

3.3

Amended and Restated Bylaws of the Registrant

S-1/A

333-203272

3.4

April 27, 2015

3.4

Certificate of Designation of Preferences, Rights and Limitations of Class X Convertible Preferred Stock

8-K

001-37378

3.1

August 31, 2017

4.1

Specimen Common Stock Certificate

S-1/A

333-203272

4.1

April 27, 2015

4.2

Warrant to Purchase Stock issued to Comerica Bank on March 18, 2011

S-1

333-203272

4.3

April 6, 2015

4.3

Warrant to Purchase Stock issued to Silicon Valley Bank on July 24, 2013

S-1

333-203272

4.4

April 6, 2015

4.4

Warrant to Purchase Stock issued to Silicon Valley Bank on November 18, 2016

10-K

001-37378

4.5

March 16, 2017

4.5

Warrant to Purchase Stock issued to Solar Capital Ltd on November 18, 2016

10-K

001-37378

4.6

March 16, 2017

4.6

Warrant to Purchase Stock issued to Silicon Valley Bank on June 30, 2017

10-Q

001-37378

4.7

August 14, 2017

4.7

Warrant to Purchase Stock issued to Solar Capital Ltd on June 30, 2017

10-Q

001-37378

4.8

August 14, 2017

4.8

Warrant to Purchase Stock issued to Silicon Valley Bank on December 22, 2017

10-K

001-37378

4.8

March 20, 2018

4.9

Warrant to Purchase Stock issued to Solar Capital Ltd on December 22, 2017

10-K

001-37378

4.9

March 20, 2018

5.1

Opinion of Cooley LLP

S-1/A

333-235951

5.1

January 27, 2020

10.1#

2014 Stock Plan and forms of agreements thereunder

S-1/A

333-203272

10.1

April 27, 2015

10.2#

2015 Stock Option and Incentive Plan, as amended

8-K

001-37378

10.1

May 10, 2019

10.3#

Forms of agreement under 2015 Stock Option and Incentive Plan

S-1/A

333-203272

10.2

April 27, 2015

10.4

Lease by and between the Registrant and BMR-John Hopkins Court LLC, dated December 22, 2011

S-1

333-203272

10.9

April 6, 2015

10.5

First Amendment to Lease between the Registrant and BMR-3545-3575 JOHN HOPKINS LP (as successor-in-interest to BMR-John Hopkins Court LLC), dated January 4, 2017

10-K

001-37378

10.8

March 16, 2017

10.6

Form of Indemnification Agreement entered into between the Registrant and its directors

S-1/A

333-203272

10.12

April 27, 2015

10.7

Form of Indemnification Agreement entered into between the Registrant and its officers

S-1/A

333-203272

10.13

April 27, 2015

10.8#

2015 Employee Stock Purchase Plan

S-1/A

333-203272

10.14

April 27, 2015

10.9#

Senior Executive Cash Incentive Bonus Plan

8-K

001-37378

10.1

January 29, 2016

II-3


 

 

Incorporated by Reference

 

Exhibit

Number

Exhibit Title

Form

File No.

Exhibit

Filing Date

10.10#

Executive Severance and Change in Control Policy

10-K

001-37378

10.16

March 30, 2016

10.11#

Registrant’s Non-Qualified Stock Option Agreement for Non-Plan Inducement Grant

10-Q

001-37378

10.1

November 14, 2016

10.12†

Loan and Security Agreement by and between the Registrant and Silicon Valley Bank and Solar Capital Ltd, dated November 18, 2016

10-K

001-37378

10.17

March 16, 2017

10.13

Second Amendment to Lease between the Registrant and BMR-3545-3575 John Hopkins LP (as successor-in-interest to BMR-John Hopkins Court, LLC), dated April 27, 2017

10-Q

001-37378

10.1

May 11, 2017

10.14

First Amendment to Loan and Security Agreement between the Registrant and Silicon Valley Bank and Solar Capital Ltd. dated June 30, 2017

10-Q

 

001-37378

10.1

August 14, 2017

10.15#

Employment Agreement, dated November 1, 2017, by and between the Company and Sanjay S. Shukla, M.D., M.S.

10-Q

 

001-37378

10.4

November 14, 2017

10.16

Second Amendment to Loan and Security Agreement between the Registrant and Silicon Valley Bank and Solar Capital Ltd. dated October 10, 2017

10-K

001-37378

10.21

March 20, 2018

10.17

Third Amendment to Loan and Security Agreement between the Registrant and Silicon Valley Bank and Solar Capital Ltd. dated December 22, 2017

10-K

001-37378

10.23

March 20, 2018

10.18

Employment Offer Letter by and between the Registrant and Jill M. Broadfoot, dated July 16, 2018

8-K

 

001-37378

10.1

August 1, 2018

10.19

Third Amendment to Lease between Registrant and BMR-3545-3575 John Hopkins LP (as successor-in interest to BMR-John Hopkins Court, LLC), dated July 30, 2018

10-Q

 

001-37378

10.1

November 14, 2018

10.20#

Employment Offer Letter by and between Registrant and Ms. Nancy Krueger, Esq., dated October 7, 2014

10-Q

001-37378

10.2

May 14, 2019

10.21

Collaboration and License Agreement by and between Registrant and Kyorin Pharmaceutical Co., Ltd. agreement, dated January 6, 2020

 

 

 

Filed herewith

10.22

Common Stock Sales Agreement, between the Registrant and H.C. Wainwright & Co., LLC, dated May 21, 2019

8-K

001-37378

10.1

May, 22, 2019

10.23

Amendment No. 1 to Common Stock Sales Agreement, dated June 18, 2019, between the Registrant and H.C. Wainwright & Co., LLC

S-3/A

333-231658

1.3

June 18, 2019

21.1

Subsidiaries of the Registrant

S-1

333-203272

21.1

April 6, 2015

23.1

Consent of Independent Registered Public Accounting Firm

S-1/A

333-235951

23.1

January 27, 2020

23.2

Consent of Cooley LLP (included in Exhibit 5.1 hereto)

S-1/A

333-235951

23.2

January 27, 2020

24.1

Powers of Attorney

S-1

333-235951

24.1

January 17, 2020

 

 

 

 

 

 

#

Indicates a management contract or compensatory plan, contract or arrangement.

Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.

II-4


 

Item 17.Undertakings

(a) The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant under the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

(c) The undersigned Registrant hereby undertakes that:

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance on Rule 430A and contained in a form of prospectus filed by the Registrant under Rule 424(b)(1) or (4) or 497(h) under the Securities Act will be deemed to be part of this registration statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities Act each post-effective amendment that contains a form of prospectus will be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will be deemed to be the initial bona fide offering thereof.

II-5


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 3, 2020.

 

 

 

 

 

 

ATYR PHARMA, INC.

 

 

By:

 

/s/ Sanjay S. Shukla, M.D., M.S.

 

 

Sanjay S. Shukla, M.D., M.S.

President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

 

 

 

 

 

Signature

  

Title

 

Date

 

 

 

/s/ Sanjay S. Shukla, M.D., M.S.

Sanjay S. Shukla, M.D., M.S.

  

President, Chief Executive Officer and Director (Principal

Executive Officer)

 

February 3, 2020

 

 

 

/s/ Jill M. Broadfoot

Jill M. Broadfoot

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

February 3, 2020

 

 

 

/s/ *

John K. Clarke

  

Chairman of the Board and Director

 

February 3, 2020

 

 

 

/s/ *

James C. Blair, Ph.D.

  

Director

 

February 3, 2020

 

 

 

/s/ *

Timothy P. Coughlin

  

Director

 

February 3, 2020

 

 

 

 

 

/s/ *

 

Director

 

February 3, 2020

Jane A. Gross, Ph.D.

  

 

 

 

 

 

 

/s/ *

Jeffrey S. Hatfield

  

Director

 

February 3, 2020

 

 

 

/s/ *

Svetlana Lucas, Ph.D.

  

Director

 

February 3, 2020

 

 

 

/s/ *

Paul Schimmel, Ph.D.

  

Director

 

February 3, 2020

 

 

 

* By: /s/ Sanjay S. Shukla, M.D., M.S.

 

 

Sanjay S. Shukla, M.D., M.S.

 

 

Attorney-in-fact

 

 

 

II-6

aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more aTyr Pharma Charts.
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more aTyr Pharma Charts.